Madrid, December 3, 2025 – The research laboratory of the Dravet Syndrome Foundation was one of the initiatives awarded 3,000 Euros in the 11th edition of the Somos Pacientes (“We are Patients”) Awards.
This award means that the Foundation will receive a grant of 3,000 euros, which will allow it to continue advancing in research into Dravet Syndrome and in support initiatives for families, with double the satisfaction of the organization both having more resources and that award being granted due to the support the initiative received from the website’s users themselves.
The award was received by Amelia Martínez, a member of the Foundation’s Board of Trustees, at a gala held at Espacio Ventas, where 10 projects related to childhood cancer, rare diseases, and inclusion were also awarded.
The Somos Pacientes Awards are organized by the Farmaindustria foundation and aim to recognize the commitment of associations that have decided to directly promote scientific projects to advance the knowledge and treatment of diseases. The foundation launched this research space in 2024 at the Science Park of the Miguel Hernández University of Elche (Alicante) and is the first patient organization to launch a similar initiative
“This award not only fills us with pride because of its importance, but also encourages us to continue working for research and improving the quality of life of families affected by Dravet Syndrome,” says the scientific director of the Dravet Syndrome Foundation, Simona Giorgi. Miguel Hernández University has recalled that the Dravet Syndrome Foundation opened its own research laboratory at the UMH Science Park last year with the aim of promoting scientific research and the search for solutions for Dravet Syndrome. The Dravet Syndrome Foundation is a pioneer among rare disease patient organizations in leading its own research laboratory. In addition to advancing more effective treatments, through this laboratory the foundation seeks to develop new open-access tools that facilitate research and, ultimately, find a cure for patients, thus improving their quality of life and that of their loved ones.
About Dravet Syndrome
Dravet Syndrome, a rare genetic disease also known as Severe Myoclonic Epilepsy of Infancy, is characterized by epileptic seizures that begin in the first year of life and a series of comorbidities that usually appear later, such as cognitive delay, behavioral problems, sleep disorders, motor and speech difficulties, and autism spectrum disorder. The mortality rate is high, reaching 15% before adulthood, mainly due to sudden unexpected death in epilepsy (SUDEP). It is caused by a mutation in the SCN1A gene and begins to manifest in the first year of life. Currently, there are between 400 and 500 diagnosed cases in Spain.
More information about Dravet Syndrome and interviews:
+34 659 207 273
